The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
HealthDay on MSN2d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Hosted on MSN7d
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Medpage Today on MSN9d
Radiographic PFS in Metastatic CRPC More Than Doubles With Novel CombinationRadiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...
“This extended real-world analysis confirms clinical practice gaps in the clinical management of mCRPC patients, ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback